Pressured by patients, FDA reviews ALS drug with modest data
WASHINGTON (AP) When patients are battling a terminal illness and want access to an experimental drug, how much evidence that it works should regulators require before approval?
Thats the question behind many of the Food and Drug Administrations toughest decisions, including last year's controversial approval of Aduhelm. Many experts including the agencys own outside advisers say that Alzheimers drug is unlikely to help patients.
Less than a year later, the agency may soon approve another drug for a deadly neurodegenerative disease based on partial data that's being debated by experts. The FDA meets next week to publicly review evidence from a small, mid-stage study of Amylyx Pharmaceuticals drug for ALS, or amyotrophic lateral sclerosis.
Regulators told Amylyx last year it would need to conduct a large, confirmatory study before seeking approval, according to the company. But after months of intense lobbying by ALS patients and their representatives in Congress, the agency said it could submit the drug based on the smaller study.
https://www.msn.com/en-us/news/politics/pressured-by-patients-fda-reviews-als-drug-with-modest-data/ar-AAVs0wt
Lost my youngest brother to ALS six years ago.